<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-44 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-44</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-44</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <p><strong>Paper ID:</strong> paper-25436023</p>
                <p><strong>Paper Title:</strong> Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data</p>
                <p><strong>Paper Abstract:</strong> Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced stages, and available systemic therapies are mostly palliative. The probing of the NSCLC kinome has identified numerous nonoverlapping driver genomic events, including epidermal growth factor receptor (EGFR) gene mutations. This review provides a synopsis of preclinical and clinical data on EGFR mutated NSCLC and EGFR tyrosine kinase inhibitors (TKIs). Classic somatic EGFR kinase domain mutations (such as L858R and exon 19 deletions) make tumors addicted to their signaling cascades and generate a therapeutic window for the use of ATP-mimetic EGFR TKIs. The latter inhibit these kinases and their downstream effectors, and induce apoptosis in preclinical models. The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. The benefits associated with these EGFR TKIs are limited by the mechanisms of tumor resistance, such as the gatekeeper EGFR-T790M mutation, and bypass activation of signaling cascades. Ongoing preclinical efforts for treating resistance have started to translate into patient care (including clinical trials of the covalent EGFR-T790M TKIs AZD9291 and CO-1686) and hold promise to further boost the median survival of patients with EGFR mutated NSCLC.</p>
                <p><strong>Cost:</strong> 0.01</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e44.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e44.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR_ethnic_freq</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ethnic and geographic differences in EGFR mutation frequency in NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mentions and quantifies differences in the prevalence of somatic EGFR activating mutations across ethnic/geographic groups (East Asian vs European/African) and in relation to smoking status, and summarizes proposed/possible explanations and noted uncertainties.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Patients with non-small-cell lung cancer (NSCLC), specifically cited groups: East Asians; patients with European or African ethnicities; never-smokers (unspecified geography).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Approximately 35% of NSCLCs in East Asians are EGFR mutation positive; approximately 15% of NSCLCs in patients with European or African ethnicities are EGFR mutation positive; approximately 50% of NSCLCs in never-smokers are EGFR mutation positive. (These overall percentages are reported in the paper.)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>East Asian: ~35% EGFR mutation positive; European/African ethnicities: ~15% EGFR mutation positive; Never-smokers (across populations): ~50% EGFR mutation positive.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Classic sensitizing mutations: exon 19 in-frame deletions (~45% of EGFR mutations), exon 21 L858R (~40%); exon 20 in-frame insertions (5-10%); exon 18 point mutations at G719 (~3%); exon 21 L861Q (~2%); exon 19 insertions (<1%). Also T790M (gatekeeper resistance mutation) is discussed (present in ~60-65% of acquired resistance cases).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>Yes â€” the paper states EGFR mutations are more frequent in never-smokers or light smokers and notes ~50% EGFR mutation positivity in never-smokers; it emphasizes that never-smoker-related NSCLCs have a distinct biology with higher incidence of targetable driver mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>The paper notes rare inherited germline EGFR mutations (e.g., germline T790M and V843I) can be associated with familial clustering of EGFR-mutant NSCLC. It also states GWAS for lung cancer susceptibility have identified a tobacco-dependent susceptibility region on chromosome 15q25.1 (CHRNA3, CHRNA5, CHRNB4), but GWAS have been relatively unrevealing of a unifying genetic basis for lung cancer in never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>No definitive molecular mechanism is provided to explain ethnic differences in EGFR mutation frequency. The paper emphasizes that the etiology (environmental or inherited) underlying selection of EGFR mutations is elusive. It discusses general molecular behavior of EGFR-activating mutations (they shift kinase equilibrium to the active state, lower ATP affinity relative to WT, create oncogene addiction and TKI sensitivity) and describes the T790M resistance mechanism (increases ATP affinity), but these are mechanistic descriptions of mutation function/sensitivity rather than explanations for why frequencies differ by ethnicity.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Primarily lung adenocarcinoma (nonsquamous NSCLC); the paper notes EGFR mutations are more frequent in adenocarcinomas and are rare in squamous cell carcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>The paper reports EGFR mutations are more frequent in women, in never-/light-smokers, and in patients of East Asian ethnicity; it also highlights that never-smoker NSCLC is a distinct clinical/biological entity.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>The paper does not endorse a definitive explanation; it explicitly states the etiology (environmental or inherited) underlying initial EGFR-mutant selection remains elusive. It suggests possible contributing factors: higher prevalence of never-smokers and female patients in some East Asian cohorts (never-smoker NSCLC has higher driver-oncogene frequency), and the existence of rare germline EGFR mutations that can predispose to familial clustering. No environmental causes or specific common germline variants explaining the population differences are proposed in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>The paper notes important uncertainties and confounders: GWAS have not identified a unifying inherited cause for never-smoker NSCLC; differences in smoking prevalence and tumor histology between populations (adenocarcinoma vs squamous) can confound apparent ethnic differences in EGFR frequency; the authors caution that the etiology is unknown and that observed differences may reflect complex interactions rather than a single cause.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data', 'publication_date_yy_mm': '2014-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>